Robert Gilliland

Retire in One Year: Build Your Freedom Plan Now 👇

$VKTX was undervalued at $85 and CEO Brian Lian reportedly rejected multiple premium buyout offers; even after hedge fund pressure pushed the stock toward $20 he has not wavered. He now indicates bidding must start around $43 B ($385 per share, the price Pfizer paid for Seagen…

$TNXP next major test sits at 52, the dip from 50 is profit taking, and holding 48–48.5 would confirm a solid base.

$TPST needs a $1B licensing deal with a major pharma, potentially a Chinese partner while Roche stays on the sidelines, with $500M upfront and $500M in milestones, a catalyst that could propel the share price another 4000% as witnessed in 2023.

$LHAI Linkhome is already profitable, generating $0.23 M in net income from $4.69 M revenue for the year to 30 June 2024, showing efficient growth that could unlock upside for early investors who buy in before the crowd takes notice.

$TNXP faces pivotal resistance at 46; a breakout with heavy volume above that level could ignite a squeeze.

$NEM generated record free cash flow of $1.71 billion, up from $594 million a year earlier, reduced debt by $372 million in the quarter, and expanded its share buyback program to $3 billion.

$DECK posted Q1 EPS of $0.93 against a $0.68 estimate, beating by $0.25, while revenue reached $964.54 M versus the $900.39 M estimate, a $64.15 M beat and a 16.9 % YoY increase. Strong demand for HOKA and UGG, healthy margins, and robust direct-to-consumer channels drove the…

$ASTS Bearish hedge funds are driving the price down, yet fresh Russell 1000 investors keep absorbing the supply; once the next catalyst is announced, the share price could accelerate quickly.

$INTC posted $12.9 billion in second quarter 2025 revenue, reflecting robust demand across key segments. Management forecasts up to $13.6 billion in third quarter revenue, signaling confidence in accelerating growth. Intel plans to trim non GAAP operating expenses to $17…

I Read Trump’s 900 Page Bill (Here’s What I Found) $QQQ $SPY $GDX $GLD $DJT

$RR isn’t a squeeze play. As belief in its products grows, patient investors should see gains.

$IOVA keeps climbing as momentum builds ahead of major catalysts and has the potential to be one of this year’s standout comebacks.

$PLTR Palantir’s CTO Shyam Sankar was in attendance, which speaks volumes.

$EBS [Strong Buy] Analysts target $15/s, implying 115 % upside from current levels Emergent is a global leader in vaccines and therapeutics for smallpox mpox anthrax botulism and ebola New NATO biosecurity spending should accelerate contract flow and topline growth Management…

$APLD will reach EPS and net income profitability faster thanks to immediate equipment and infrastructure expensing paired with streamlined building permits.

$VKTX reported EPS of ($0.58) Vs Zacks’ forecast of ($0.44) reflecting the cost of vigorous clinical activity rather than operational weakness. Cash and cash equivalents slipped from $851 M on March 31 to $808 M on June 30, signifying a disciplined $45 M burn while advancing…

$GOOG Est. $2.18 | $195–$198 or breakout to $202 | +3% to +6% $2.21 | $198–$202 or breakout to $207 | +5% to +9%

$QBTS an attractive entry point right now. Catalysts on the horizon position the stock for a run toward $50.

$AVXL peer reviewed JPAD article endorsed by 55 Alzheimer authorities reports excellent data with even stronger long-term OLE results. Non-cancer candidates at this stage carry over 95 % EMA approval odds. Experts value a European approval at $33 B and a U S approval at $46 B,…

$LCID has 385.5 M shares sold short at $2.80, creating a $1.08 B short position. If the company executes a 1 for 10 reverse split the share count would drop to 38.55 M while the price would rise to $28.00, leaving the position’s value unchanged at $1.08 B. The higher share price…